Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.